KRAS and pachyonychia congenita: Moreover, new molecules targeting downstream kinases of mutant K-Ras are currently investigated to overcome K-Ras induced drug resistance: MAP2K, though its inhibition has been only partly effective in PC therapy (159, 160) or MEK, known as one of the most significant downstream kinase of K-Ras signaling.